NewsRx

Search our medical news database

Ovarian Cancer

Entremed commences Phase 2 clinical trial with Panzem NCD in ovarian cancer

Published in Women's Health Weekly, December 7th, 2006

EntreMed, Inc. (ENMD), a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced commencement of a multicenter, Phase 2 clinical trial with its clinical stage drug candidate, Panzem NCD (2ME2 or 2-methoxyestradiol), in patients with recurrent or resistant epithelial ovarian cancer.

The study will be conducted by the Hoosier Oncology Group, headquartered in Indianapolis. Daniela E. Matei, MD, assistant professor, Department of Medicine, Division of Hematology/Oncology, Indiana University Cancer Center, will serve as Principal Investigator.

Primary objectives for this single-agent...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook